By Iain Gilbert
Date: Friday 03 May 2024
(Sharecast News) - Liquid biopsy technology firm Angle has struck a supplier deal with pharmaceutical giant AstraZeneca to develop an androgen receptor detection assay to enhance prostate cancer studies.
Angle said on Friday that the agreement was an extension of a previous arrangement to develop a methodology for detecting CTC micronuclei,...
or login to read the full story
Email this article to a friend
or share it with one of these popular networks:
You are here: news